Beam Therapeutics Inc. (BEAM) vs Dyne Therapeutics, Inc. (DYN)

Beam Therapeutics Inc. and Dyne Therapeutics, Inc. are both Biotechnology companies. Dyne Therapeutics, Inc. is the larger, with a market value of $2.9B against $2.6B — 1.1× the size. Dyne Therapeutics, Inc. has the higher net margin (0.00% vs −55.5%) and the lower return on invested capital (−1,956.3% vs −1,599.3%). Across the 14 metrics below, Beam Therapeutics Inc. leads on 10 and Dyne Therapeutics, Inc. on 4.

Valuation

Metric BEAM DYN Biotechnology median
P/E n/m n/m 8.50
P/S 15.69 n/m 9.71
P/B 2.29 3.36 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.95 n/m 9.21
Earnings yield (3.49%) (23.37%) (33.15%)
Free cash flow yield (15.22%) (20.38%) (25.50%)

Profitability

Metric BEAM DYN Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (242.27%) 0.00% 0.00%
Net margin (55.45%) 0.00% 0.00%
Free cash flow margin (238.90%) 0.00% 0.00%
Return on equity (8.18%) (81.57%) (56.36%)
Return on assets (6.23%) (60.29%) (48.04%)
Return on invested capital (1,599.30%) (1,956.27%) 0.00%

Growth

Metric BEAM DYN Biotechnology median
Revenue growth (TTM) 158.88% — 6.02%
EPS growth (last fiscal year) 82.31% (2.97%) 30.26%
Revenue growth, 5-year CAGR 466.27% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM DYN Biotechnology median
Debt to equity 0.09 0.30 0.00
Current ratio 14.57 12.02 4.72
Net debt to EBITDA 3.30 2.05 0.96

Dividend

Metric BEAM DYN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BEAM DYN Biotechnology median
Market cap 2.55b 2.86b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack